| Literature DB >> 15740617 |
Anne Marie Lynge Pedersen1, Allan Bardow, Birgitte Nauntofte.
Abstract
BACKGROUND: the classification criteria for primary Sjogren's syndrome (pSS) include a number of oral components. In this study we evaluated if salivary flow and composition as well as dental caries are oral markers of disease severity in pSS.Entities:
Year: 2005 PMID: 15740617 PMCID: PMC554998 DOI: 10.1186/1472-6890-5-4
Source DB: PubMed Journal: BMC Clin Pathol ISSN: 1472-6890
Anamnestic data and results of self-assessed oral dryness of the female patients with primary Sjögren's syndrome (pSS) and the female healthy controls. Results are given as number of patients or scores (yes/no) and as means ± SD.
| pSS ( | Healthy controls ( | P-value | |
| Age (years) | 60 ± 15 | 56 ± 13 | 0.437a |
| Duration of disease (years)* | 6 ± 7 | 0 | NA |
| Duration of symptoms (years) | 10 ± 7 | 0 | NA |
| Xerogenic medicines (yes/no)† | 7/13 | 0/20 | NA |
| Smokers (yes/no)§ | 5/15 | 0/20 | NA |
| Cigarettes per day (smokers only)§ | 7 (2–20) | 0 | NA |
| Tooth brushing (times per day) | 3 ± 1 | 2 ± 1 | 0.001a |
| Dental floss and/or toothpicks daily (yes/no) | 16/4 | 15/5 | 1.000b |
| Dental visits per year (number) | 3 ± 1 | 2 ± 1 | 0.001a |
| Oral dryness (score 0/1/2/3) | 0/3/4/13 | 20/0/0/0 | <0.001b |
* The time from established diagnosis to present examination. †Patients were interviewed regarding their intake of medicines. Their intake of xerogenic medicines included antidepressants, antihistamines and β-blocking agents [20]. §Patients were also interviewed regarding their smoking habits, since cigarette smoking has been shown to reduce the extent of labial salivary gland lymphocytic infiltration [23] and to have a negative impact on periodontal status. Smoking, however, has no impact on salivary flow or composition [24].
P-values obtained by a two-sample t-test (a) and Fisher exact test (b). NA; not analyzed.
Oral findings in the patients with primary Sjögren's syndrome (pSS) and the healthy controls. Results are given as number of patients or scores (yes/no) and in medians (ranges).
| pSS ( | Healthy controls ( | P-value | |
| No. of teeth | 22 (6–28) | 28 (0–28) | 0.011a |
| DMFS* | 83.0 (25–140) | 43.0 (10–140) | 0.001a |
| Distribution of D/M/FS | 23/745/1020 | 14/305/662 | <0.001b |
| Subjects with dentures (yes/no) | 4/16 | 7/13 | 0.480c |
| Distribution of PI (no. of 0/1/2/3 scores) | 245/179/54/2 | 244/152/60/0 | 0.272b |
| Distribution of GI (no. of 0/1/2/3 scores) | 346/116/16/2 | 330/95/31/0 | 0.034b |
| Probing pocket depth (PPD, mm) | 2 (1–4) | 2 (1–3) | 0.523a |
*D/M/FS, decayed, missed, filled surfaces; PI, plaque index; GI, gingival index. P-values obtained by Wilcoxon rank sum test (a), Chi2- test (b), and Fisher exact test (c).
Unstimulated (UWS) and stimulated (SWS) whole salivary flow rate and composition in the patients with primary Sjögren's syndrome (pSS, n = 20) and the healthy controls (n = 20). Results are given in median (range).
| UWS | SWS | |||||
| pSS | Healthy controls | P-value | pSS | Healthy controls | P-value | |
| Flow rate (ml/min) | 0.02 (0.00–0.23) ( | 0.39 (0.06–1.10) ( | <0.001 | 0.14 (0.01–1.66) ( | 1.40 (0.54–2.82) ( | <0.001 |
| Na+ (mM) | 12.0 (8.0–47.0) ( | 8.0 (4.5–17.0) ( | 0.008 | 16.0 (8.0–59.0) ( | 10.3 (5.5–30.0) ( | 0.020 |
| K+ (mM) | 22.2 (5.1–48.0) ( | 21.9 (6.8–33.4) ( | 0.536 | 21.6 (15.2–34.6) ( | 22.0 (11.5–26.5) ( | 0.533 |
| Total calcium (mM) | 2.0 (1.3–3.2) ( | 1.7 (0.5–2.8) ( | 0.285 | 1.3 (0.7–1.9) ( | 1.3 (0.8–2.5) ( | 0.558 |
| Cl- (mM) | 25.8 (16.0–62.0) ( | 18.3 (5.2–26.0) | 0.003 | 22.6 (13.5–58.6) ( | 16.1 (10.5–28.6) ( | 0.037 |
| Total phosphate (mM) | 6.0 (1.2–15.0) ( | 6.8 (2.4–11.7) ( | 0.961 | 4.4 (2.4–8.5) ( | 4.1 (1.6–11.5) ( | 0.606 |
| Total protein (mg/ml) | 3.00 (1.52–8.84) ( | 3.29 (1.36–6.25) (n = 19) | 0.560 | 3.50 (0.421–8.93) ( | 3.04 (1.23–5.54) ( | 0.491 |
| Total protein output (mg/min) | 0.210 (0.06–0.80) ( | 1.09 (0.50–2.38) ( | <0.001 | 0.95 (0.11–4.33) (n = 12) | 3.88 (2.35–8.06) ( | <0.001 |
| Amylase activity (μkat/l) | 365 (0–4500) ( | 980 (0–8940) ( | 0.155 | 1490 (0–4080) ( | 2280 (0–5890) ( | 0.199 |
P-value obtained by Wilcoxon's rank sum test.
Unstimulated (UPS) and stimulated (SPS) parotid salivary flow rates, composition including pH, PCO2, buffer capacity, degree of saturation with regard to hydroxyapatite, and critical pH in the patients with primary Sjögren's syndrome (pSS, (n = 20)) and the healthy controls (n = 20). Results are given in medians (range).
| UPS | SPS | |||||
| pSS | Healthy controls | P-value | pSS | Healthy controls | P-value | |
| Flow rate (ml/min/gland) | 0.00* (0.00–0.04) ( | 0.04 (0.00–0.13) ( | <0.001 | 0.10 (0.00–0.87) ( | 0.72 (0.17–1.57) ( | <0.001 |
| pH | 5.5 (4.9–6.2) ( | 6.1 (5.4–6.6) ( | 0.008 | 6.8 (5.3–7.6) ( | 7.1 (6.8–8.0) ( | 0.020 |
| PCO2 (KPa) | 2.5 (2.1–4.8) ( | 3.3 (0.5–7.9) ( | 0.455 | 3.5 (1.4–7.5) ( | 5.5 (0.3–10.0) ( | 0.021 |
| Na+ (mM) | 7.0 (0.0–111.0) ( | 0.0 (0.0–8.5) ( | 0.002 | 15.5 (3.5–93.0) ( | 7.5 (0.0–65.0) ( | 0.034 |
| K+ (mM) | 24.5 (4.5–52.5) ( | 29.0 (17.5–62.0) ( | 0.209 | 26.5 (12.0–53.0) ( | 23.0 (18.0–40.0) ( | 0.689 |
| Total calcium (mM) | 1.0 (0.4–2.4) ( | 1.0 (0.6–4.1) ( | 0.887 | 1.1 (0.6–1.8) ( | 0.8 (0.4–1.4) ( | 0.008 |
| Cl- (mM) | 22.5 (5.0–100.5) ( | 19.0 (12.0–43.0) ( | 0.588 | 27.0 (12.5–94.0) ( | 15.5 (9.0–59.0) ( | 0.037 |
| Bicarbonate (mM) | 0.2 (0.0–0.8) ( | 0.8 (0.1–3.5) ( | 0.017 | 3.6 (0.1–26.8) ( | 11.3 (3.8–43.9) ( | 0.025 |
| Total phosphate (mM) | 5.6 (2.3–15.0) ( | 9.3 (4.1–18.9) ( | 0.066 | 6.1 (2.1–8.2) ( | 5.2 (3.2–16.9) ( | 0.577 |
| Total protein (mg/ml) | 1.11 (0.47–8.97) ( | 2.02 (0.64–5.34) ( | 0.316 | 1.33 (0.62–6.66) ( | 1.60 (0.84–4.19) ( | 0.589 |
| Total protein output (mg/min) | 0 (0–0.18) ( | 0.07 (0–0.30) ( | <0.001 | 0.13 (0–1.38) ( | 1.30 (0.29–5.42) ( | <0.001 |
| Amylase activity (μkat/l) | 7760 (3700–21200) | 5815 (1670–27140) | 0.193 | 5220 (560–17240) | 5520 (710–14710) | 0.624 |
| β(mmol H+/l. pH unit) | 1.2 (0.1–2.9) ( | 4.0 (2.3–8.9) ( | <0.001 | 4.4 (0.5–6.7) ( | 5.2 (0.7–10.1) ( | 0.171 |
| DSHAP | 1.4 (0.2–3.6) ( | 3.1 (2.5–10.4) ( | 0.001 | 7.3 (0.6–21.4) ( | 10.0 (4.5–22.0) ( | 0.372 |
| Critical pH | 5.4 (5.1–6.2) ( | 5.3 (5.0–5.5) ( | 0.413 | 5.5 (5.2–6.2) ( | 5.7 (5.2–5.8) ( | 0.611 |
The buffer capacity (β) was calculated from the bicarbonate and phosphate concentrations individually for each saliva sample at its pH value, DSHAP denotes the degree of saturation with regard to hydroxyapatite. P-value obtained by a Wilcoxon's rank sum test. * corresponds to mean value below 0.01 ml/min.
Figure 1shows the saliva composition as a function of the parotid saliva flow rate (both unstimulated and stimulated) in patients with pSS (bold circles) and healthy age-matched controls (open circles). Lines were fitted by linear (a and b) or non-linear regression (c-h) depending on the best obtainable fit judged from the R-squared values with unbroken lines representing pSS and dotted lines the controls. Figures 1a and b illustrates that the pSS patients can be divided into two subgroups with regard to salt reabsorption. One group of patients follow the reabsorption pattern of the healthy controls, whereas the other group display high sodium and chloride concentrations despite low parotid flow rates indicating differences in the degree of glandular affection by the disease of the patients studied.
Explanatory power of age as well as subjective and objective salivary variables on DMFS in the patient group and control group all together (n = 40).
| Estimate for DMFS | SD for DMFS estimate | Adjusted R-squared | P-value | |
| Subjective model | ||||
| Age | 1.4 | 0.4 | 0.26 | <0.001 |
| + oral dryness questionnaire | 11.1 | 2.3 | 0.53 | <0.001 |
| Objective model | ||||
| Age | 1.4 | 0.4 | 0.26 | <0.001 |
| + UWS | -57.4 | 20.7 | 0.37 | <0.001 |
| + SWS | -28.9 | 9.4 | 0.49 | <0.001 |
| + UPS | -499.2 | 173.0 | 0.57 | <0.001 |
Estimate, SD, adjusted R-squared, and P-value obtained by multiple regression analysis. The estimate states the increase or decrease in DMFS upon addition of the explaining variables (age + oral dryness, or + UWS, SWS, and UPS) by an integer (one year, score, or ml). Since complaints of oral dryness and salivary flow demonstrated strong interrelations they could not be included in the same analysis. As shown age in combination with complaints of oral dryness explained 53% of the variance in DMFS, and age combined with salivary flow rates explained 57%.